Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9586965
APP PUB NO 20150210702A1
SERIAL NO

14420341

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ACEA THERAPEUTICS INC9380 JUDICIAL DRIVE SAN DIEGO CA 92121

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Mao, Long San Diego, US 28 282
Wang, Xiaobo San Diego, US 339 5652
Xi, Biao San Diego, US 25 292
Xu, Xiao San Diego, US 131 2804
Zhao, Li San Diego, US 242 1872

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 7, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00